Atopic Dermatitis/Atopic Eczema | Disease Landscape and Forecast | G7 | 2017

AD is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard AD treatments aim to protect the skin barrier through moisturization and to reduce inflammation and pruritus. Topical corticosteroids and topical immunomodulators are the mainstays of AD treatment in patients whose disease is not adequately controlled by emollients alone. Additionally, ultraviolet light and systemic immunomodulators are used to treat topical-refractory AD. Topical therapies are often effective for mild disease; however, more-effective therapies for severe AD are sorely needed. The AD pipeline is burgeoning, owing to the unmet need and commercial opportunity for improved AD therapeutics; this is highlighted by the recent launch of Pfizer’s topical Eucrisa (crisaborole) and Sanofi/Regeneron’s Dupixent (dupilumab), as well as the large number of diverse mid- to late-phase programs (e.g., IL-13 inhibitors, JAKinhibitors, IL-31 inhibitors). This report provides a comprehensive analysis of current ADmanagement, the impact of recent market entrants, lingering unmet needs, and the clinical and commercial potential of emerging drugs.


What are the sizes of key patient subpopulations and how will they change by 2026? How well are these populations served by current AD therapies?

How will the launches of Pfizer’s Eucrisa, Sanofi/Regeneron’s Dupixent, and emerging programs alter the AD treatment landscape?

What emerging therapies are in development for AD? Which are best poised to achieve commercial success, and why?

Where are the key unmet needs and commercial opportunities in the AD space? To what extent will emerging therapies address these needs?


Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Login to access report